160 related articles for article (PubMed ID: 38074816)
1. PTPN3 in cancer: unveiling its immune-mediated impact on prognosis and dysregulated signaling pathways.
Abdel-Maksoud MA; Ullah S; Nadeem A; Khan QUA; Zia MK; Ali S; Zakri AM; Almanaa TN; Alfuraydi AA; Al-Qahtani WH; Hameed Y
Am J Transl Res; 2023; 15(11):6464-6475. PubMed ID: 38074816
[TBL] [Abstract][Full Text] [Related]
2. Immune modulation and prognostic significance of MCM10 in pan-cancer: a comprehensive analysis.
Abdel-Maksoud MA; Iqbal K; Gull S; Kumar SK; Mastoor M; Almutairi SM; Almanaa TN; Alfuraydi AA; Mubarak A; Kotob MH; Jamil M; Zaky MY
Am J Transl Res; 2023; 15(11):6451-6463. PubMed ID: 38074804
[TBL] [Abstract][Full Text] [Related]
3. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract][Full Text] [Related]
4. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology.
Hu H; Umair M; Khan SA; Sani AI; Iqbal S; Khalid F; Sultan R; Abdel-Maksoud MA; Mubarak A; Dawoud TM; Malik A; Saleh IA; Al Amri AA; Algarzae NK; Kodous AS; Hameed Y
Am J Transl Res; 2024; 16(2):432-445. PubMed ID: 38463578
[TBL] [Abstract][Full Text] [Related]
5. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
7. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
Zhang X; Wu Z; Ma K
BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
[TBL] [Abstract][Full Text] [Related]
8. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
9. An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy.
Feng M; Cui H; Tu W; Li L; Gao Y; Chen L; Li D; Chen X; Xu F; Zhou C; Cao Y
Front Genet; 2022; 13():975381. PubMed ID: 36105075
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics immune regulatory mechanisms in lung adenocarcinoma metastasis and survival time.
Liu D; Yao L; Ding X; Zhou H
Comput Biol Med; 2023 Sep; 164():107333. PubMed ID: 37586202
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2 Serves as a Prognostic Biomarker and Correlated With Immune Infiltrates in Breast Invasive Cancer and Lung Adenocarcinoma.
Xiao X; Shan H; Niu Y; Wang P; Li D; Zhang Y; Wang J; Wu Y; Jiang H
Front Mol Biosci; 2022; 9():647826. PubMed ID: 35558557
[TBL] [Abstract][Full Text] [Related]
12. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis.
Abdel-Maksoud MA; Ullah S; Nadeem A; Shaikh A; Zia MK; Zakri AM; Almanaa TN; Alfuraydi AA; Mubarak A; Hameed Y
Am J Transl Res; 2024; 16(1):63-74. PubMed ID: 38322551
[TBL] [Abstract][Full Text] [Related]
13. PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling.
Peng XS; Yang JP; Qiang YY; Sun R; Cao Y; Zheng LS; Peng LX; Lang YH; Mei Y; Li CZ; Meng DF; Liu ZJ; Wang MD; Zhou FJ; Huang BJ; Qian CN
Mol Cancer Res; 2020 Jun; 18(6):903-912. PubMed ID: 32169891
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
15. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis and WDFY4 as novel targets for immunotherapy of lung adenocarcinoma.
Huang L; Zhong L; Cheng R; Chang L; Qin M; Liang H; Liao Z
Aging (Albany NY); 2023 Sep; 15(18):9676-9694. PubMed ID: 37728413
[TBL] [Abstract][Full Text] [Related]
18. PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Koga S; Onishi H; Masuda S; Fujimura A; Ichimiya S; Nakayama K; Imaizumi A; Nishiyama K; Kojima M; Miyoshi K; Nakamura K; Umebayashi M; Morisaki T; Nakamura M
Transl Oncol; 2021 Sep; 14(9):101152. PubMed ID: 34134073
[TBL] [Abstract][Full Text] [Related]
19. AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma.
Fan D; Yang M; Lee HJ; Lee JH; Kim HS
Front Mol Biosci; 2023; 10():1265359. PubMed ID: 37908231
[No Abstract] [Full Text] [Related]
20. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
